home / stock / alim / alim news

ALIM News and Press, Alimera Sciences Inc. From 07/13/22

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
ALIM - Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress

ATLANTA, July 13, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ALIM - Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences ( NASDAQ: ALIM ) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement ...

ALIM - Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...

ALIM - Alimera's partner Ocumension gets China regulator nod to start diabetic macular edema study

Alimera Sciences (NASDAQ:ALIM) its partner Ocumension Therapeutics received approval from China's National Medical Products Administration (NMPA) for an application seeking to begin a phase 3 trial of fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). DME is a ...
ALIM - Phase III Clinical Study IND Accepted in China for Alimera's Fluocinolone Acetonide Intravitreal Implant

ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...

ALIM - Alimera Sciences to Present at the LD Micro Invitational XII Conference

ATLANTA, June 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...

ALIM - Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

ATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced tod...
ALIM - Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q1 2022 Results - Earnings Call Transcript

Alimera Sciences, Inc (ALIM) Q1 2022 Earnings Conference Call May 09, 2022, 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital ...

ALIM - Alimera Sciences GAAP EPS of -$0.85 misses by $0.16, revenue of $11.89M misses by $1.01M

Alimera Sciences press release (NASDAQ:ALIM): Q1 GAAP EPS of -$0.85 misses by $0.16. Revenue of $11.89M (+6.1% Y/Y) misses by $1.01M. For further details see: Alimera Sciences GAAP EPS of -$0.85 misses by $0.16, revenue of $11.89M misses by $1.01M

ALIM - Alimera Sciences Reports First Quarter 2022 Results

Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 U.S. Net Revenue Increased 23% vs. First Quarter of 2021 U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc....
Previous 10 Next 10